Ads
related to: kite pharma- Experts
Our experts are on hand to help you
solve drug development challenges.
- Formulation Optimization
Rapid drug product optimization
Integrated to accelerate timelines
- Locations
State-of-the-art drug manufacturing
facilities and expertise. UK & US.
- Drug Substance Expertise
Move your drug substance supply off
the critical path. Contact us today
- Accelerate Your Program
Use Translational Pharmaceutics®
to accelerate your drug development
- Contact
Contact our experts about your
drug development programs & needs
- Experts
Search results
Kite Pharma's CAR T-Cell Therapy Wins European Approval In Refractory Leukemia Setting
Benzinga via Yahoo Finance· 2 years agoThe European Commission has approved Gilead Science Inc (NASDAQ: GILD) company Kite Pharma's CAR...
Gilead to lay off staff at cell therapy unit Kite
BioPharma Dive via Yahoo Finance· 6 months agoDive Brief: Gilead Sciences is laying off about 7% of employees at cell therapy unit Kite Pharma in a restructuring it said is meant to better align the...
Europe Approves First CAR T-Cell Therapy For B-Cell Lymphoma In 30 Years to Improve Upon Standard of...
Benzinga via Yahoo Finance· 2 years agoThe European Commission approved Kite Pharma's, a Gilead Sciences Inc (NASDAQ: GILD) Yescarta...
Gilead expands Arcellx cancer cell therapy deal
BioPharma Dive via Yahoo Finance· 7 months agoDive Brief: Gilead is expanding its collaboration with cancer cell therapy developer Arcellx, announcing Wednesday that subsidiary Kite Pharma has used...
US Supreme Court Throws Out Bristol Myers Appeal On Cancer-Drug Related Patent With Gilead
Benzinga via Yahoo Finance· 2 years agoThe U.S. Supreme Court turned away an appeal made by rebuffed efforts made by Bristol Myers Squibb...
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences
Investor's Business Daily· 1 year agoRecent initial public offering Arcellx forged a $325 million multiple myeloma deal with Gilead...
U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead
Reuters via Yahoo Finance· 2 years agoWASHINGTON (Reuters) -The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's...
Arcellx Inc (ACLX) Reports Q3 2023 Financial Results and Business Updates
GuruFocus.com via Yahoo Finance· 7 months agoArcellx Inc (NASDAQ:ACLX) announces promising updates on CART-ddBCMA trial with median follow-up of 22 months. Financials show $482.7 million in cash reserves, funding operations into 2026.
FDA says cancer treatment CAR-T therapy may cause cancer itself
Newsy via AOL· 4 months agoGrowing bacteria to create CAR-T therapy The Food and Drug Administration will require companies...
See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch
Investor's Business Daily· 2 years agoGilead Sciences' first-in-class cancer drug and GILD stock are finally hitting their stride. The...
